Open Label Pilot Efficacy and Safety Study of GLYX-13 in Subjects with Neuropathic Pain

aurex, Inc. (USA)0 个研究点目标入组 100 人开始时间: 2014年11月24日最近更新: 2015年7月6日

适应症

试验速览

暂无简介。

•1. Male and female subjects
•2. 18-75 years of age
•3. Currently taking pain medications but pain is not adequately controlled, or currently not taking pain medication due to intolerance or lack of efficacy
•4. Subjects who have experienced neuropathic pain not excluded in the exclusion criteria for 6 months or longer with pain score of 30/100 or greater by VAS at screening visit.
•5. Female subjects of childbearing potential with a negative serum pregnancy test prior to entry into the study and who are practicing an adequate method of birth control (eg oral or parenteral contraceptives, intrauterine device, barrier, abstinence) and who do not plan to become pregnant during the course of the study. Female subjects may be included without a negative serum pregnancy test if they are surgically sterile or at least 2 years post-menopausal.
•6. Male subjects who are abstinent during the course of the study or who use a condom during sexual intercourse.
•7. Clinical laboratory values <2 times the upper limit of normal (ULN) or deemed not clinically significant per the investigator and Naurex medical monitor
•8. Ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assesments

•1. Currently hospitalized or residing in an in-patient facility during study participation
•2. Substance abuse including greater than or equal to 5 units of alcohol per day where 1 unit = ½ pint of beer, 1 glass of wine 4 oz, or 1 oz. of spirits consumed most weeks or in the opinion of the investigator
•3. Women who are planning to become pregnant during the course of the study
•4. Participation in any clinical trial of an investigational product or device within 30 days of enrollment in this study.
•5. Positive screen for drugs of abuse: cocaine, marijuana, PCP, ketamine, opioid or other agent that in the opinion of the investigator is being abused
•6. Human immunodeficiency virus (HIV) infection (based on the based on the HIV-1 & HIV-2 antibody screen) or other ongoing infectious disease
•7. Pain as a consequence of chemotherapeutic agent for any disease, alcohol- or HIV-induced neuropathic pain.
•8. History of separate pain condition, eg, osteoarthritis that is more severe than the neuropathic pain syndrome
•9. Lumbar-sacral radiculopathy or failed low back surgery
•10. Pain with nerve injury expected to recover within 4 months
•11. Complex regional pain syndrome type I
•12. Concomitant peripheral neuropathy, paresthesia or dysthesia which cannot be differentiated from neuropathic pain due to other than neuropathic mechanism

发起方

aurex, Inc. (USA)